These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9381549)

  • 1. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.
    Wissing KM; Morelon E; Legendre C; De Pauw L; LeBeaut A; Grint P; Maniscalki M; Ickx B; Vereerstraeten P; Chatenoud L; Kreis H; Goldman M; Abramowicz D
    Transplantation; 1997 Oct; 64(7):999-1006. PubMed ID: 9381549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
    Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS
    Transplantation; 1996 Feb; 61(4):573-7. PubMed ID: 8610383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome.
    Eason JD; Pascual M; Wee S; Farrell M; Phelan J; Boskovic S; Blosch C; Mohler KM; Cosimi AB
    Transplantation; 1996 Jan; 61(2):224-8. PubMed ID: 8600628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids.
    Chatenoud L; Ferran C; Legendre C; Thouard I; Merite S; Reuter A; Gevaert Y; Kreis H; Franchimont P; Bach JF
    Transplantation; 1990 Apr; 49(4):697-702. PubMed ID: 2109379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis.
    Herbelin A; Abramowicz D; de Groote D; Naret C; Kreis H; Bach JF; Goldman M; Chatenoud L
    Transplantation; 1999 Sep; 68(5):616-22. PubMed ID: 10507478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3.
    DeVault GA; Kohan DE; Nelson EW; Holman JM
    Transplantation; 1994 Feb; 57(4):532-40. PubMed ID: 8116037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OKT3 first-dose reaction: association with T cell subsets and cytokine release.
    Gaston RS; Deierhoi MH; Patterson T; Prasthofer E; Julian BA; Barber WH; Laskow DA; Diethelm AG; Curtis JJ
    Kidney Int; 1991 Jan; 39(1):141-8. PubMed ID: 1900552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites.
    Chatenoud L; Legendre C; Ferran C; Bach JF; Kreis H
    Transplantation; 1991 Feb; 51(2):334-8. PubMed ID: 1899732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of indomethacin on the febrile response following OKT3 therapy.
    First MR; Schroeder TJ; Hariharan S; Alexander JW; Weiskittel P
    Transplantation; 1992 Jan; 53(1):91-4. PubMed ID: 1733091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human tumor necrosis factor receptor Fc fusion protein therapy in kidney transplant recipients undergoing OKT3 induction therapy.
    Novak EJ; Blosch CM; Perkins JD; Davis CL; Barr D; McVicar JP; Griffin RS; Farrand AL; Wener M; Marsh CL
    Transplantation; 1998 Dec; 66(12):1732-5. PubMed ID: 9884268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection.
    Reinke P; Schwinzer H; Höflich C; Ode-Hakim C; Döcke WD; Frei U; Volk HD
    Immunol Lett; 1997 Jun; 57(1-3):151-3. PubMed ID: 9232443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients.
    Abramowicz D; Goldman M; Mat O; Estermans G; Crusiaux A; Vanherweghem JL; De Pauw L; Kinnaert P; Vereerstraeten P
    Transpl Int; 1994 Jul; 7(4):258-63. PubMed ID: 7916925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients.
    Vallhonrat H; Williams WW; Cosimi AB; Tolkoff-Rubin N; Ginns LC; Wain JC; Preffer F; Olszak I; Wee S; Delmonico FL; Pascual M
    Transplantation; 1999 Jan; 67(2):253-8. PubMed ID: 10075589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy.
    Wee S; Pascual M; Eason JD; Schoenfeld DA; Phelan J; Boskovic S; Blosch C; Mohler K; Cosimi AB
    Transplantation; 1997 Feb; 63(4):570-7. PubMed ID: 9047153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients.
    Abramowicz D; Schandene L; Goldman M; Crusiaux A; Vereerstraeten P; De Pauw L; Wybran J; Kinnaert P; Dupont E; Toussaint C
    Transplantation; 1989 Apr; 47(4):606-8. PubMed ID: 2523100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of OKT3 increases with dosage: a controlled study in renal transplant recipients.
    Parlevliet KJ; Bemelman FJ; Yong SL; Hack CE; Surachno J; Wilmink JM; ten Berge IJ; Schellekens PT
    Transpl Int; 1995; 8(2):141-6. PubMed ID: 7766296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.